Skip to main content

Table 1 Characteristics of proteomics cohorts in discovery stage and in validation stage

From: Proteomics and metabolomics profiling reveal panels of circulating diagnostic biomarkers and molecular subtypes in stable COPD

 

Discovery stage

Pa

Validation stage

Pa

COPD

Controls

COPD

Controls

N

40

40

 

29

31

 

Male, %

100

100

1.0

100

100

1.0

Smoking, %

100

100

1.0

100

100

1.0

Packyears ≥ 30, %

100

100

1.0

100

100

1.0

Age (years), mean (SD)

64.6 (11.7)

63.7 (5.3)

0.656

   

Height (cm), mean (SD)

165.0 (5.2)

166.0 (5.9)

0.824

164 (4.9)

169 (5.9)

< 0.001

Weight (kg), mean (SD)

63.1 (12.5)

65.7 (8.2)

0.266

60.60 (9.3)

69.10 (9.4)

0.001

BMI (kg/m2), mean (SD)

23.8 (2.9)

23.1 (4.6)

 

22.40 (3.2)

23.90 (2.5)

0.054

Fan in kitchen, %

93.2

92.7

0.475

92.3

93.6

1.000

Good room ventilation, %

38.6

63.4

0.022

62.1

51.6

0.414

Often preserved food, %

18.8

7.1

0.106

10.3

3.2

0.346

Often cook, %

25.0

29.3

0.658

17.2

35.5

0.110

Comorbidity, %

 CRD

29.8

12.2

0.045

34.6

3.2

0.002

 Hypertension

42.6

31.7

0.294

34.6

22.6

0.314

 Diabetes

12.8

7.5

0.498

0

10

–

 Heart diseases

40.4

12.5

0.004

19.2

6.7

0.231

 Stroke

4.3

0

–

3.8

0

–

Family history, %

 Cancer

6.3

9.5

0.563

23.1

22.6

0.965

 RD without COPD

19.1

15.8

0.759

7.1

3.2

–

 Severe COPD, %

100

0

–

100

0

–

Pulmonary function, mean (SD)

 pre_FVC_%Pred

74.9 (28.1)

98.0 (15.0)

< 0.001

78.5 (16.3)

94.3 (10.4)

< 0.001

 pre_FEV1_%Pred

59.7 (32.1)

88.4 (26.1)

< 0.001

47.1 (14.3)

94.5 (9.6)

< 0.001

 pre_FEV1/FVC_%Pred

62.7 (15.9)

71.3 (15.5)

0.036

57.4 (15.8)

96.8 (9.7)

< 0.001

 post_FVC_%Pred

74.6 (24.6)

99.8 (12.5)

< 0.001

88.3 (14.6)

104 (13.0)

0.061

 post_FEV1_%Pred

57.1 (28.6)

90.8 (25.4)

< 0.001

53.8 (15.8)

101 (10.4)

< 0.001

 post_FEV1/FVC_%Pred

60.7 (15.2)

70.9 (15.4)

0.021

57.7 (15.4)

76.9 (6.3)

0.025

  1. Bold values indicate significant differences
  2. CRD chronic respiratory disease, severe COPD Global Initiative for Obstructive Lung Disease stage 3–4
  3. aP-values for a two-sided χ2 test or t-test. Data are median (P25–P75), n (%)